Information  X 
Enter a valid email address

Veos PLC (VEO)


Monday 20 March, 2000

Veos PLC

European Patent Approval for Oves (TM) Device

Veos PLC
20 March 2000



Veos plc ('Veos' or 'the Company'), the AIM listed female healthcare company,
is pleased to announce that its patent for a version of its drug-loaded
Oves(TM)cap has been approved by the European Patent Office.

Veos' concept is to make the cap in pieces - each piece with a different
biological activity which would then be 'snapped together' by a pharmacy based
on a doctor's prescription to provide a sustained drug delivery platform
specific to the requirements of the individual patient. The assembled cap
would then be taken home by the patient and put in place for the length of
time specified by her doctor. The benefit to the patient is that treatment is
not reliant on their compliance to 'take' medication on a regular schedule.

Veos has already developed the technology to be able to load silicon with
drugs.  However the Company has formulated a technique which allows a cap to
be loaded with more than one drug and therefore able to deliver the necessary
permutation of dosages and types of drugs to treat Sexually Transmitted
Diseases ('STDs'), pelvic inflammatory disease, yeast, kidney or bladder
infections.  Each drug will be loaded by the manufacturer of that drug.  As a
result, no drug company needs to disclose proprietary formulations to the
Company or other third parties.  This enables Veos to select the best drug for
each treatment required.

Commenting on this announcement, Peggy Czyzak-Dannenbaum, Chairman and Chief
Executive of Veos, said:

'Following our successful launch on AIM at the end of last year, we are
delighted that our next announcement should be about European Patent approval
for a new development.  This ability to load a vaginal device with multiple
drugs will have wide applications for the treatment of different diseases and
infections, in particular, STDs, and we believe it will be a powerful tool for
Doctors to use in female healthcare.'

For further information, please contact:

Peggy Czyzak-Dannenbaum, Chairman and Chief Executive
Veos plc                                                   Tel: 0171 643 2233

David Simonson / Melanie Toyne Sewell
Merlin Financial                                           Tel: 0171 606 1244

Notes to Editors

Veos, incorporated in 1999, owns the patent and worldwide distribution rights
to the Oves(TM) product range, which currently consists of a revolutionary
female contraceptive cap a conception cap and additional applications in
protection against sexually transmitted diseases (STDs) and drug delivery
under development.  The Oves(TM) contraceptive cap is a discrete, disposable
and hygienic silicone device developed over the last decade using proven
female barrier contraceptive technologies.

In December 1999, the Company listed on the Alternative Investment Market and
raised £6.5 million (gross) of new capital by way of an institutional Placing.
The Ordinary shares of 10p each were placed at 71p per share, valuing the
Group at £16.2million.   As at 17 March 2000 the shares were at 109p with a
market capitalisation of £24 million.  Williams de Broe is Nominated Advisor
and Broker.


a d v e r t i s e m e n t